
    
      The objective of this observational study is to collect and evaluate data on bronchodilator
      efficacy and safety of Spiriva® (18 µg tiotropium inhalation capsules) delivered by
      HandiHaler®, in national sample of Russian patients with varying severities of chronic
      obstructive pulmonary disease (COPD) in the real life setting over the 8 weeks.

      Study Hypothesis:

      Primary interest is given to observe change from baseline in post-dose FEV1 after 8 weeks.

      Comparison(s):

      The objective of this observational study is to collect and evaluate data on bronchodilator
      efficacy and safety of Spiriva® (18 mcg tiotropium inhalation capsules) delivered by
      HandiHaler®, in national sample of Russian patients with varying severities of chronic
      obstructive pulmonary disease (COPD) in a real life setting over the 8 weeks.
    
  